The ceramide synthase family, often referred to as LASS (longevity assurance homologs), encompasses a group of enzymes crucial in sphingolipid metabolism. These enzymes are responsible for the synthesis of ceramides, a type of lipid molecule that plays a key role in cell membrane integrity and signaling pathways. Each ceramide synthase isoform (CerS1-6 in humans) prefers different fatty acyl-CoA substrates, leading to the production of ceramides with distinct acyl chain lengths. The ceramides synthesized by these enzymes are involved in various cellular processes, including apoptosis, cell proliferation, and stress response. Dysregulation of ceramide synthase activity is linked to numerous diseases, including cancer, neurodegenerative disorders, and metabolic conditions. Additionally, ceramides act as signaling molecules, influencing pathways like inflammation and cell survival, and are integral to the formation of lipid rafts in cell membranes.
Targeting ceramide synthase (LASS) for disruption or inhibition using small molecules is a strategic approach for understanding its biological functions and implications in diseases. By selectively inhibiting specific isoforms of ceramide synthase, researchers can elucidate the distinct roles of different ceramide species in cellular processes. Small molecule inhibitors allow for precise modulation of ceramide levels, facilitating studies on how changes in ceramide synthesis affect cellular signaling pathways. This approach is critical for dissecting the complex sphingolipid metabolism pathways and their impact on cell physiology. Inhibiting ceramide synthase can reveal insights into the mechanisms of diseases like cancer, where ceramide levels are often dysregulated.
VEJA TAMBÉM
Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
---|---|---|---|---|---|---|
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $117.00 $469.00 | 18 | |
Um inibidor da ceramida sintase que pode reduzir a atividade do LASS4 ao inibir competitivamente a função da enzima. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
Este inibidor não competitivo da esfingomielinase neutra pode influenciar os níveis de ceramida, regulando a expressão de LASS4. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Um inibidor da farnesiltransferase, que possivelmente afecta a modificação pós-traducional das proteínas que regulam o LASS4. | ||||||
Ceranib-2 | 1402830-75-4 | sc-507503 | 10 mg | $173.00 | ||
Um inibidor específico da ceramida sintase que pode diminuir a atividade do LASS4 por inibição direta. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Um inibidor da autofagia que pode afetar a renovação dos componentes celulares, incluindo o LASS4. | ||||||
Desipramine hydrochloride | 58-28-6 | sc-200158 sc-200158A | 100 mg 1 g | $65.00 $115.00 | 6 | |
Inibe a esfingomielinase ácida e pode resultar numa alteração do metabolismo dos esfingolípidos, com potencial impacto no LASS4. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $240.00 | 9 | |
Inibe a fosfolipase C específica da fosfatidilcolina, afectando a degradação da esfingomielina e, por extensão, os níveis de ceramida que podem influenciar o LASS3. | ||||||
SKI II | 312636-16-1 | sc-204286 sc-204286A | 10 mg 50 mg | $94.00 $392.00 | 3 | |
Inibe a esfingosina quinase, que pode influenciar os níveis de esfingosina-1-fosfato e a síntese de ceramida, afectando potencialmente o LASS3. | ||||||
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | $104.00 $315.00 | ||
Induz a síntese de ceramidas, influenciando potencialmente a atividade de LASS3 através de mecanismos de feedback. | ||||||
Sphingomyelin | 85187-10-6 | sc-201381 sc-201381A | 100 mg 500 mg | $163.00 $520.00 | 3 | |
Bloqueia a ceramida sintase, incluindo a LASS3, levando a uma diminuição da síntese de ceramida. |